Weiss Ulrike, Bacher Reinhard, Vonbank Herbert, Kemmler Georg, Lingg Albert, Marksteiner Josef
Department of Psychiatry, University of Innsbruck, Austria.
J Clin Psychiatry. 2003 Mar;64(3):235-42. doi: 10.4088/jcp.v64n0303.
In vivo proton magnetic resonance spectroscopy is a safe and noninvasive tool that can be used to study aspects of brain chemistry and metabolism. This study was designed to evaluate its role in routine application to reveal the diagnostic reasons for cognitive impairment.
37 Alzheimer's disease patients (NINCDS-ADRDA criteria), 31 patients with subcortical ischemic vascular dementia (Chui et al. criteria), and 13 subjects with subjective cognitive impairment (DSM-IV criteria) were included in this retrospective study. Magnetic resonance images were used for atrophy rating; additionally, proton magnetic resonance spectroscopy was performed.
Significantly reduced N-acetylaspartate levels (p <.05) were found in both patients with Alzheimer's disease and patients with subcortical ischemic vascular dementia compared to the group with subjective memory complaints. The ratios of N-acetylaspartate/creatine and N-acetylaspartate/myo-inositol were significantly lower in Alzheimer's disease patients compared to patients with vascular dementia (p =.012) or patients with subjective memory impairment (p =.002). N-acetylaspartate/creatine and N-acetylaspartate/myo-inositol ratios were positively correlated to the degree of cerebral atrophy. Disoriented patients displayed a low N-acetylaspartate/creatine ratio. In contrast, we were not able to relate concurrent psychotic or behavioral symptoms to any spectroscopic parameter.
This study indicates that proton magnetic resonance spectroscopy parameters could provide additional information in differentiating between Alzheimer's disease, subcortical ischemic vascular dementia, and subjective cognitive impairment. Therefore, this method can contribute to the routine diagnosis of dementia. Psychiatric and behavioral symptoms associated with dementia or due to a major psychiatric disorder cannot be related to changes in the measured proton magnetic resonance spectroscopy parameters.
体内质子磁共振波谱是一种安全无创的工具,可用于研究脑化学和代谢方面。本研究旨在评估其在常规应用中揭示认知障碍诊断原因的作用。
本回顾性研究纳入了37例阿尔茨海默病患者(符合NINCDS - ADRDA标准)、31例皮质下缺血性血管性痴呆患者(符合Chui等人的标准)和13例主观认知障碍患者(符合DSM - IV标准)。使用磁共振图像进行萎缩评级;此外,还进行了质子磁共振波谱分析。
与主观记忆障碍组相比,阿尔茨海默病患者和皮质下缺血性血管性痴呆患者的N - 乙酰天门冬氨酸水平均显著降低(p <.05)。与血管性痴呆患者(p =.012)或主观记忆障碍患者(p =.002)相比,阿尔茨海默病患者的N - 乙酰天门冬氨酸/肌酸和N - 乙酰天门冬氨酸/肌醇比值显著更低。N - 乙酰天门冬氨酸/肌酸和N - 乙酰天门冬氨酸/肌醇比值与脑萎缩程度呈正相关。定向障碍患者的N - 乙酰天门冬氨酸/肌酸比值较低。相比之下,我们无法将并发的精神病性或行为症状与任何波谱参数相关联。
本研究表明,质子磁共振波谱参数可为区分阿尔茨海默病、皮质下缺血性血管性痴呆和主观认知障碍提供额外信息。因此,该方法有助于痴呆的常规诊断。与痴呆相关或由主要精神障碍导致的精神和行为症状与所测量的质子磁共振波谱参数变化无关。